Would you restart endocrine therapy for a patient with new contralateral LCIS diagnosed 2 years following completion of AI therapy for stage 1A HR+ IDC?

The primary prevention trials (NSABP-1, STAR, etc) largely excluded women with a prior history of cancer and certainly did not include those who'd had 5 previous yrs of endocrine therapy. While I think you could discuss an additional 5 yrs of endocrine therapy, an additional 5 yrs of AI (e.g. 5-10 t...